Ignite Creation Date:
2025-12-26 @ 10:32 AM
Ignite Modification Date:
2026-01-01 @ 12:10 AM
Study NCT ID:
NCT06984328
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-12-02
First Post:
2025-05-14
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)
Sponsor:
Genmab
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-07-25
Start Date Type:
ACTUAL
Primary Completion Date:
2027-07-15
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-07-15
Completion Date Type:
ESTIMATED
First Submit Date:
2025-05-14
First Submit QC Date:
None
Study First Post Date:
2025-05-22
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-01
Last Update Post Date:
2025-12-02
Last Update Post Date Type:
ESTIMATED